Treatment of melanoma metastases confined to the liver and future perspectives

Digestive Surgery

Volumn 25, Issue 6, 2009, Pages 467-472

  Vahrmeijer, Alexander L ^a   Van De Velde, Cornelis J H ^a   Hartgrink, Henk H ^a   Tollenaar, Rob A E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Liver metastases; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; FOTEMUSTINE; MELPHALAN;

CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CONFERENCE PAPER; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; LIVER PERFUSION; LIVER RESECTION; TREATMENT RESPONSE; UVEA MELANOMA;

CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EYE NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 60149087726     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000184738     Document Type: Conference Paper

References (30)

1. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T: Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000;107:1443-1449.
2. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS: Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76:1665-1670.
3. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem P, V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-1125.
4. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Brocker EB: Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002;87:840-845.
5. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G: Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006;244:524-535.
6. Herman P, Machado MA, Montagnini AL, D'Albuquerque LA, Saad WA, Machado MC: Selected patients with metastatic melanoma may benefit from liver resection. World J Surg 2007;31:171-174.
7. Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL: Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001;136:950-955.
8. Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, Rosato EL, Rosato FE, Sato T: Protracted survival after resection of metastatic uveal melanoma. Cancer 2000;89:1561-1568.
9. Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Aloia TA, Curley SA, Camacho LH, Capussotti L, Elias D, Vauthey JN: Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006;13:712-720.
10. Rothbarth J, Pijl ME, Vahrmeijer AL, Hartgrink HH, Tijl FG, Kuppen PJ, Tollenaar RA, van de Velde CJH: Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003;90:1391-1397.
11. van Iersel LB, Verlaan MR, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Sparidans RW, Gelderblom H, Kuppen PJ, Tollenaar RA, van de Velde CJH: Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol 2007;33:874-881.
12. van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJH: Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 2008;19:1127-1134.
13. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de Velde CJH: Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000;82:1539-1546.
14. Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR: Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 2004;8:200-207.
15. Rizell M, Mattson J, Cahlin C, Hafstrom L, Lindner P, Olausson M: Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res 2008;18:120-126.
16. van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJH: Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 2008;15:1891-1898.
17. Alexander HR Jr, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T: Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003;9:6343-6349.
18. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S: Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006;17:578-583.
19. Siegel R, Hauschild A, Kettelhack C, Kahler KC, Bembenek A, Schlag PM: Hepatic arterial fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007;33:627-632.
20. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L: Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589-2595.
21. Cantore M, Pederzoli P, Cornalba G, Fiorentini G, Guadagni S, Miserocchi L, Frassoldati A, Ceravolo C, Smerieri F, Muchmore JH: Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 2000;11:569-573.
22. Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK, Dayani PN, Brown DB: Hepatic arterial chemoembolization for management of metastatic melanoma. Am J Roentgenol 2008;190:99-104.
23. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S: Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988;260:974-976.
24. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD: Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98:383-389.
25. Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S: Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 2008;18:220-224.
26. van der Werff MP, Mertens B, de Noo ME, Bladergroen MR, Dalebout HC, Tollenaar RA, Deelder AM: Case-control breast cancer study of MALDI-TOF proteomic mass spectrometry data on serum samples. Stat Appl Genet Mol Biol 2008;7:Article2 Epub.
27. Mertens BJ, de Noo ME, Tollenaar RA, Deelder AM: Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm. J Comput Biol 2006;13:1591-1605.
28. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH: Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol 2006;12:6594-6601.
29. Pardo M, Dwek RA, Zitzmann N: Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery. Expert Rev Proteomics 2007;4:273-286.
30. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di CS, Martins C, Fernandes BF, Burnier MN Jr: Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008;14:951-956.